{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T16:57:12Z","timestamp":1782493032740,"version":"3.54.5"},"reference-count":44,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T00:00:00Z","timestamp":1777766400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>\n                      <jats:italic toggle=\"yes\">Pneumocystis jirovecii<\/jats:italic>\n                      pneumonia (PJP) is increasingly recognized among immunocompromised adults without HIV, yet prophylaxis use remains inconsistent. Data describing cumulative and overlapping immunosuppressive exposures before PJP diagnosis are limited.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To characterize immunosuppressive exposure patterns and evaluate use of PJP-active therapy among non-HIV, nonhematopoietic cell transplant (non-HCT) adults with PJP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This retrospective cohort study (2011-2024) used the TriNetX Research Network. Adults without HIV or prior HCT with laboratory-confirmed PJP (positive polymerase chain reaction or antigen from respiratory specimens) were included. Demographics, comorbidities, and exposure to glucocorticoids (GCs), antineoplastics (ANs), and immunosuppressants (ISs) within 90 days before diagnosis were assessed. Overlapping immunosuppressive regimens and their associations with receipt of PJP-active therapy were evaluated. Because prescribing indication and dosing were unavailable, prescriptions for trimethoprim\/sulfamethoxazole, atovaquone, dapsone, or pentamidine were grouped as PJP-active therapy, representing prophylactic, preemptive, or empiric use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Among 578 adults with PJP, 87% received GCs, 37% ANs, and 26% ISs. More than half (54%) were exposed to 2 or more drug classes, whereas 10% had no identifiable immunosuppressive medication exposure. Despite frequent multidrug immunosuppression, only 32% received PJP-active therapy before diagnosis. GC exposure was more common among patients who received PJP-active therapy (97% vs 82%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001), while AN and IS exposures did not differ between groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion and Relevance:<\/jats:title>\n                    <jats:p>PJP in non-HIV, non-HCT adults commonly occurs in the setting of frequent multidrug immunosuppression. These findings reveal a disconnect between cumulative immunosuppressive risk and prophylaxis practices and support approaches that incorporate overall immunologic burden rather than single-agent thresholds.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10600280261443794","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T05:52:23Z","timestamp":1777873943000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["<i>Pneumocystis jirovecii<\/i>\n                    Pneumonia in Non-HIV, Non-HCT Adults: Real-World Patterns of Overlapping Immunosuppression and PJP-Active Therapy"],"prefix":"10.1177","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4018-0195","authenticated-orcid":false,"given":"Daniel B.","family":"Chastain","sequence":"first","affiliation":[{"name":"Department of Clinical and Administrative Pharmacy, University of Georgia College of Pharmacy, Augusta, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dustin M.","family":"Solorzano-Salazar","sequence":"additional","affiliation":[{"name":"Universidad Peruana de Ciencias Aplicadas, Santiago de Surco, Per\u00fa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Mantha","sequence":"additional","affiliation":[{"name":"Divisions of Pulmonary Sciences and Critical Care Medicine and Infectious Diseases, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reed","family":"Van Hook","sequence":"additional","affiliation":[{"name":"Divisions of Pulmonary Sciences and Critical Care Medicine and Infectious Diseases, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Maloney","sequence":"additional","affiliation":[{"name":"Divisions of Pulmonary Sciences and Critical Care Medicine and Infectious Diseases, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"George R.","family":"Thompson","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, University of California-Davis Medical Center, Sacramento, USA"},{"name":"Department of Medical Microbiology and Immunology, University of California, Davis Medical Center, Sacramento, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Yu","family":"Chiu","sequence":"additional","affiliation":[{"name":"Divisions of Pulmonary Sciences and Critical Care Medicine and Infectious Diseases, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leland","family":"Shapiro","sequence":"additional","affiliation":[{"name":"Divisions of Pulmonary Sciences and Critical Care Medicine and Infectious Diseases, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, USA"},{"name":"Rocky Mountain Regional Veterans Affairs Medical Center, Aurora, Colorado, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niyah","family":"Brown","sequence":"additional","affiliation":[{"name":"Department of Clinical and Administrative Pharmacy, University of Georgia College of Pharmacy, Athens, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s F.","family":"Henao-Mart\u00ednez","sequence":"additional","affiliation":[{"name":"Divisions of Pulmonary Sciences and Critical Care Medicine and Infectious Diseases, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,5,3]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/mmy\/myae038"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2022.100400"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12281-024-00482-8"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw157"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2020.07.029"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(23)00692-8"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005590.pub2"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197712292972602"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.13587"},{"key":"e_1_3_3_11_2","unstructured":"NCCN. Prevention and treatment of cancer-related infections version 1.2025. Accessed July 3 2025. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/infections.pdf"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223335"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjab052"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad474"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaf147"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-024-03308-y"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid1903.121151"},{"issue":"4","key":"e_1_3_3_18_2","first-page":"671","article-title":"Pneumocystis jiroveci pneumonia in rheumatic disease: a 20-year single-centre experience","volume":"35","author":"Mecoli CA","year":"2017","unstructured":"Mecoli CA, Saylor D, Gelber AC, Christopher-Stine L. Pneumocystis jiroveci pneumonia in rheumatic disease: a 20-year single-centre experience. Clin Exp Rheumatol. 2017;35(4):671-673.","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-1996-6"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaf390"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.12.052"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/jamiaopen\/ooad035"},{"key":"e_1_3_3_23_2","unstructured":"TriNetX. Accessed November 24 2025. https:\/\/trinetx.com\/real-world-resources\/case-studies-publications\/trinetx-publication-guidelines\/"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1805"},{"key":"e_1_3_3_25_2","unstructured":"Panel on guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV. National Institutes of Health Centers for Disease Control and Prevention HIV Medicine Association and Infectious Diseases Society of America. Accessed November 24 2025. https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/adult-and-adolescent-opportunistic-infection"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0000000000001002"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2020000116"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.4065\/71.1.5"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc070728"},{"key":"e_1_3_3_30_2","unstructured":"WHO. Anatomical Therapeutic Chemical (ATC) classification. Accessed June 6 2025. https:\/\/www.who.int\/tools\/atc-ddd-toolkit\/atc-classification"},{"key":"e_1_3_3_31_2","unstructured":"Larsson J. eulerr: area-proportional Euler and Venn diagrams with ellipses. R package version 6.1.1. Accessed June 9 2025. https:\/\/CRAN.R-project.org\/package=eulerr"},{"key":"e_1_3_3_32_2","unstructured":"Larsson J Gustafsson P. A case study in fitting area-proportional Euler diagrams with ellipses using eulerr. Accessed July 3 2025. https:\/\/ceur-ws.org\/Vol-2116\/paper7.pdf"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.3390\/jof7080625"},{"issue":"2","key":"e_1_3_3_34_2","first-page":"246","article-title":"Pneumocystis carinii pneumonia in the course of connective tissue disease: report of 34 cases","volume":"21","author":"Godeau B","year":"1994","unstructured":"Godeau B, Coutant-Perronne V, Le Thi Huong D, et al. Pneumocystis carinii pneumonia in the course of connective tissue disease: report of 34 cases. J Rheumatol. 1994;21(2):246-251.","journal-title":"J Rheumatol"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.7883\/yoken.JJID.2018.400"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0344273"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1097\/tp.0000000000003576"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-022-02300-8"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.09.013"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz315"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/2464791"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1080\/00365540601150497"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1111\/tid.12651"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1007\/pl00021707"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae239"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280261443794","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10600280261443794","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280261443794","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T08:49:04Z","timestamp":1778143744000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10600280261443794"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,3]]},"references-count":44,"alternative-id":["10.1177\/10600280261443794"],"URL":"https:\/\/doi.org\/10.1177\/10600280261443794","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,3]]},"article-number":"10600280261443794"}}